towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma towards improved death receptor targeted therapy for ... - TI Pharma
Chapter 3 MAPK p38 and JNK have opposing activities on TRAIL‐ induced apoptosis activation in NSCLC cells that involves RIP1 and caspase‐8 and is mediated by Mcl‐1 Kaamar Azijli, Saravanan Yuvaraj, Ingrid van Roosmalen, Koen Flach, Elisa Giovannetti, Godefridus J. Peters, Steven de Jong, Frank A.E. Kruyt Apoptosis (Accepted, in press)
Chapter 3 ABSTRACT Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) can induce both caspase‐ dependent apoptosis and kinase activation in tumor cells. Here, we examined the consequences and mechanisms of TRAIL‐induced MAPKs p38 and JNK in non‐small cell lung cancer (NSCLC) cells. In apoptosis sensitive H460 cells, these kinases were phosphorylated, but not in resistant A549 cells. Time course experiments in H460 cells showed that induction of p38 phosphorylation preceded that of JNK. To explore the function of these kinases in apoptosis activation by TRAIL, chemical inhibitors or siRNAs were employed to impair JNK or p38 functioning. JNK activation counteracted TRAIL‐ induced apoptosis whereas activation of p38 stimulated apoptosis. Notably, the serine/threonine kinase RIP1 was cleaved following TRAIL treatment, concomitant with detectable JNK phosphorylation. Further examination of the role of RIP1 by short hairpin (sh)RNA‐dependent knockdown or inhibition by necrostatin‐1 showed that p38 can be phosphorylated in both RIP1‐dependent and ‐independent manner, whereas JNK phosphorylation occurred independent of RIP1. On the other hand JNK appeared to suppress RIP1 cleavage via an unknown mechanism. In addition, only the activation of JNK by TRAIL was caspase‐8‐dependent. Finally, we identified Mcl‐1, a known substrate for p38 and JNK, as a downstream modulator of JNK or p38 activity. Collectively, our data suggest in a subset of NSCLC cells a model in which TRAIL‐induced activation of p38 and JNK have counteracting effects on Mcl‐1 expression leading to pro‐ or anti‐apoptotic effects, respectively. Strategies aiming to stimulate p38 and inhibit JNK may have benefit for TRAIL‐based therapies in NSCLC. Key Words: TRAIL, kinases, combination therapy, lung cancer ‐ 40 ‐
- Page 2 and 3: TRAIL-induced kinases activation an
- Page 4 and 5: TRAIL‐induced kinases activation
- Page 6: “In order to be irreplaceable one
- Page 9 and 10: ‐ 8 ‐
- Page 11 and 12: Chapter 1 GENERAL INTRODUCTION Canc
- Page 13 and 14: Chapter 1 OUTLINE OF THE THESIS As
- Page 15 and 16: Chapter 1 Reference List 1. Jemal A
- Page 17 and 18: Chapter 2 ABSTRACT Tumor necrosis f
- Page 19 and 20: Chapter 2 INTRODUCTION The death li
- Page 21 and 22: Chapter 2 In preclinical studies, a
- Page 23 and 24: Chapter 2 Table 1| Summary of the k
- Page 25 and 26: Chapter 2 proliferation could be pr
- Page 27 and 28: Chapter 2 Figure 2. Canonical and n
- Page 29 and 30: Chapter 2 associated with TRAIL res
- Page 31 and 32: Chapter 2 adhesion molecules [109].
- Page 33 and 34: Chapter 2 Reference List 1. Ashkena
- Page 35 and 36: Chapter 2 37. Tolcher AW, Mita M, M
- Page 37 and 38: Chapter 2 melanoma cells from TRAIL
- Page 39: Chapter 2 and ERK pathways. Circula
- Page 43 and 44: Chapter 3 inhibitors and TRAIL rece
- Page 45 and 46: Chapter 3 of amplification of the t
- Page 47 and 48: Chapter 3 P38 and JNK have opposing
- Page 49 and 50: Chapter 3 Figure 2 (continued). (e)
- Page 51 and 52: Chapter 3 previously established H4
- Page 53 and 54: Chapter 3 effect on TRAIL‐induced
- Page 55 and 56: Chapter 3 induced apoptosis in H460
- Page 57 and 58: Chapter 3 Reference List 1. Jemal A
- Page 59 and 60: Chapter 3 40. Domina AM, Vrana JA,
- Page 61 and 62: Chapter 4 ABSTRACT Tumor necrosis f
- Page 63 and 64: Chapter 4 role in the activation of
- Page 65 and 66: Chapter 4 the tip with a diameter o
- Page 67 and 68: Chapter 4 RESULTS TRAIL induces a s
- Page 69 and 70: Chapter 4 vehicle control or with 5
- Page 71 and 72: Chapter 4 Non‐canonical TRAIL res
- Page 73 and 74: Chapter 4 A549‐shRIP1 cells clear
- Page 75 and 76: Chapter 4 Figure 7. Inhibition of S
- Page 77 and 78: Chapter 4 DISCUSSION The TRAIL rece
- Page 79 and 80: Chapter 4 Src‐independent mechani
- Page 81 and 82: Chapter 4 variants. Cell Death Dis
- Page 83 and 84: Chapter 4 ‐ 82 ‐
- Page 85 and 86: Chapter 5 ABSTRACT TRAIL is an inte
- Page 87 and 88: Chapter 5 targets and subsequent pr
- Page 89 and 90: Chapter 5 RESULTS Synergistic activ
Chapter 3<br />
MAPK p38 and JNK have opposing activities on TRAIL‐<br />
induced apoptosis activation in NSCLC cells that<br />
involves RIP1 and caspase‐8 and is mediated by Mcl‐1<br />
Kaamar Azijli, Saravanan Yuvaraj, Ingrid van Roosmalen, Koen Flach, Elisa<br />
Giovannetti, Godefridus J. Peters, Steven de Jong, Frank A.E. Kruyt<br />
Apoptosis (Accepted, in press)
Change language